Literature DB >> 2241503

Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness.

N C Andreasen1, V W Swayze, M Flaum, W R Yates, S Arndt, C McChesney.   

Abstract

We evaluated ventricular-brain ratio with computed tomographic scanning in a sample of 108 DSM-III-diagnosed schizophrenic patients and 75 healthy normal volunteers. Significant differences were noted between the patients and controls, but our large sample size also permitted us to determine that the statistically significant difference was contributed primarily through the male patients. Ventricular enlargement occurs only in some schizophrenic patients. In this particular sample, only 6% of schizophrenics had ventricular-brain ratios greater than 2 SDs from the control mean, and 28% were 1 SD greater than the control mean. However, the corresponding figures for male schizophrenics were 19% and 43%, indicating that there is much less overlap between normal individuals and ill subjects in the male population. First-admission schizophrenic patients also had significantly greater ventricular enlargement than did their age-equivalent normal controls, suggesting that ventricular enlargement in schizophrenia may antedate the onset of symptoms. Examination of ventricular size in schizophrenics and normal subjects from a broad age range suggests that ventricular enlargement does not progress over time at a greater rate in schizophrenic patients than in normal subjects.

Entities:  

Mesh:

Year:  1990        PMID: 2241503     DOI: 10.1001/archpsyc.1990.01810230024005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

1.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics.

Authors:  G J Popken; W E Bunney; S G Potkin; E G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Abnormalities of cingulate gyrus neuroanatomy in schizophrenia.

Authors:  Lei Wang; Malini Hosakere; Joshua C L Trein; Alex Miller; J Tilak Ratnanather; Deanna M Barch; Paul A Thompson; Anqi Qiu; Mokhtar H Gado; Michael I Miller; John G Csernansky
Journal:  Schizophr Res       Date:  2007-04-11       Impact factor: 4.939

3.  Dementia as a complication of schizophrenia.

Authors:  P J de Vries; W G Honer; P M Kemp; P J McKenna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

4.  Affectively salient meaning in random noise: a task sensitive to psychosis liability.

Authors:  Mariana Galdos; Claudia Simons; Aranzazu Fernandez-Rivas; Marieke Wichers; Concepción Peralta; Tineke Lataster; Guillermo Amer; Inez Myin-Germeys; Judith Allardyce; Miguel Angel Gonzalez-Torres; Jim van Os
Journal:  Schizophr Bull       Date:  2010-04-01       Impact factor: 9.306

5.  Computed tomographic findings in schizophrenia: relation with symptom dimensions and sex differences.

Authors:  A K Malla; J Takhar; R M Norman; L Assis
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

6.  The hormonal environment in utero as a potential aetiological agent for schizophrenia.

Authors:  Marco Procopio; Russel J E Davies; Paul Marriott
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-29       Impact factor: 5.270

7.  Factors related to integrating persons with chronic mental illness into a peer social milieu.

Authors:  S Levin; J S Brekke
Journal:  Community Ment Health J       Date:  1993-02

Review 8.  Sex steroids and schizophrenia.

Authors:  Julie A Markham
Journal:  Rev Endocr Metab Disord       Date:  2012-09       Impact factor: 6.514

9.  The relationship of structural brain imaging parameters to antipsychotic treatment response: a review.

Authors:  L Friedman; C Lys; S C Schulz
Journal:  J Psychiatry Neurosci       Date:  1992-06       Impact factor: 6.186

10.  Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia.

Authors:  Marquis P Vawter; Cynthia Shannon Weickert; Erick Ferran; Mitsuyuki Matsumoto; Kevin Overman; Thomas M Hyde; Daniel R Weinberger; William E Bunney; Joel E Kleinman
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.